Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28632005 | 1.00 | ABCB1 (0.34) | ABCB1PLA2G4A | |
| SCHEMBL28634045 | 0.91 | ABCB1 (0.33) | ABCB1 | |
| SCHEMBL22154599 | 0.91 | ABCB1 (0.33) | ABCB1 | |
| SCHEMBL30360070 | 0.89 | ABCB1 (0.35) | ABCB1PLA2G4A | |
| SCHEMBL22154694 | 0.88 | ABCB1 (0.36) | ABCB1PLA2G4A | |
| SCHEMBL28646537 | 0.85 | GAA (0.37) | — | |
| SCHEMBL28631048 | 0.84 | ABCB1 (0.43) | ABCB1PLA2G4A | |
| SCHEMBL28631046 | 0.84 | ABCB1 (0.43) | ABCB1PLA2G4A | |
| SCHEMBL31232797 | 0.82 | — | — | |
| SCHEMBL28627110 | 0.81 | ABCB1 (0.33) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | ABCB1 895/4885PLA2G4A 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.